Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: A phase 1b, open-label, maximal-use systemic exposure study

Pediatric Dermatology

Volumn 33, Issue 4, 2016, Pages 380-387

  Zane, Lee T ^a   Kircik, Leon ^b   Call, Robert ^c   Tschen, Eduardo ^d   Draelos, Zoe Diana ^e   Chanda, Sanjay ^a   Van Syoc, Merrie ^a   Hebert, Adelaide A ^f  

^a PFIZER INC   (United States)

^b Physicians Skin Care PLLC   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d Academic Dermatology Associates   (United States)

^e DERMATOLOGY CONSULTING SERVICES   (United States)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRISABOROLE;

ADOLESCENT; APPLICATION SITE PAIN; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84978043629     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/pde.12872     Document Type: Article

References (16)

1. Bieber T. Atopic dermatitis. N Engl J Med 2008;358:1483–1494.
2. Eichenfield LF, Tom WL, Berger TG et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014;71:116–132.
3. Carroll CL, Balkrishnan R, Feldman SR et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005;22:192–199.
4. Sidbury R, Davis DM, Cohen DE et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014;71:327–349.
5. Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 2007;8:364–372.
6. Baumer W, Hoppmann J, Rundfeldt C et al. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007;6:17–26.
7. Higgs G. Is PDE4 too difficult a drug target? Curr Opin Investig Drugs 2010;11:495–498.
8. Akama T, Baker SJ, Zhang YK et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 2009;19:2129–2132.
9. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs 2009;10:1236–1242.
10. Kalavala M, Dohil MA. Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence. Am J Clin Dermatol 2011;12:15–24.
11. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs 2013;15:303–310.
12. Ellison JA, Patel L, Ray DW et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000;105:794–799.
13. Hengge UR, Ruzicka T, Schwartz RA et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1–15.
14. Freund YR, Akama T, Alley MR et al. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett 2012;586:3410–3414.
15. Zane LT, Tom WL, Chanda S et al. Safety, pharmacokinetics and efficacy of AN2728 ointment, 2% in a phase 2 study of adolescents with mild-to-moderate atopic dermatitis. Poster presented at the International Investigative Dermatology Meeting, Edinburgh, Scotland, May 8–11, 2013.
16. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;60:44–47.